{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiclymifzlhp6vytw37zbwjwslistikh6og5brtym53fmilsrng5aa",
    "uri": "at://did:plc:oznbnvgr7dmvddiyvr7dih52/app.bsky.feed.post/3mkkltor5b7p2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreic5cicafm3q4xgwzm3ths6f63t7pip3cwbafd27wvr3m247yodsdi"
    },
    "mimeType": "image/jpeg",
    "size": 43257
  },
  "path": "/health/recall-pill-antidepressant-sertraline-citalopram",
  "publishedAt": "2026-04-28T12:22:01.000Z",
  "site": "https://www.gbnews.com",
  "tags": [
    "Simple seated exercise helps control blood sugar levels in just three minutes",
    "'I'm a neurologist and I avoid these three everyday habits over a rare stroke risk'",
    "Britons spending fewer years free of illness as figures show decade-long health decline",
    "The GB News Editorial Charter"
  ],
  "textContent": "\n\n\nThe Medicines and Healthcare products Regulatory Agency has issued a precautionary recall affecting a single batch of Sertraline 100mg tablets after discovering the wrong antidepressant medication had been placed inside some packaging.\n\nAmarox Limited, the manufacturer, is withdrawing batch number V2500425 of its film-coated sertraline tablets following the identification of a packaging mix-up.\n\n###\n\n\n\n\nThe error came to light after a patient reported finding Citalopram 40mg tablets inside their sealed sertraline carton.\n\nBoth medications belong to the SSRI class of antidepressants, which function by increasing serotonin levels in the brain to treat depression and anxiety disorders.\n\n###\n\n\n\n\nTRENDING\n\nStories\n\nVideos\n\nYour Say\n\n###\n\n\n\n\nPatients prescribed sertraline who possess this particular batch have been urged to inspect their medication immediately.\n\nIt appears the manufacturing fault took place during the secondary packaging process, when blister strips are placed into their outer cartons.\n\nSince Amarox Limited produces both sertraline and citalopram at the same production site, the mix-up resulted in a citalopram blister strip ending up inside a sertraline box.\n\n###\n\n\n\n\n###\n\n\n\n\n\n\n\nThe MHRA has classified this as a Class 2 recall, prompting swift action from the regulator to protect public safety.\n\nAnyone who suspects they may have inadvertently consumed the incorrectly packaged citalopram tablets, or who is experiencing any adverse effects, should seek medical guidance without delay.\n\nDr Alison Cave, the MHRA's Chief Safety Officer, has provided clear instructions for those who may be affected.\n\n### LATEST DEVELOPMENTS\n\n\n\n\n  * Simple seated exercise helps control blood sugar levels in just three minutes\n  * 'I'm a neurologist and I avoid these three everyday habits over a rare stroke risk'\n  * Britons spending fewer years free of illness as figures show decade-long health decline\n\n\n\n###\n\n\n\n\n\"If you have been prescribed Sertraline 100mg tablets and have received batch number V2500425, please check that the carton contains the right medication. You can find the batch number and expiry date printed on the side of the outer packaging,\" she said.\n\n\"If the blister strips inside the carton are labelled Citalopram 40mg, please contact your pharmacy as soon as possible. If they are labelled \"Sertraline 100mg\", no further action is needed.\"\n\nDr Cave noted individuals who have mistakenly taken citalopram alongside or instead of their prescribed sertraline may notice heightened serotonergic effects, including nausea, headaches, disrupted sleep patterns, and mild anxiety.\n\n###\n\n\n\n\n###\n\n\n\n\nHealthcare professionals have been directed to cease supplying the affected batch immediately and return all remaining stock to their suppliers.\n\nPharmacists and other dispensing staff must identify patients who may have received the compromised product and request its return if any medication remains.\n\n###\n\n\n\n\n###\n\n\n\n\nWhere affected patients are identified, healthcare professionals should liaise with the patient's GP or responsible clinician to arrange a treatment review and determine whether a fresh prescription is necessary.\n\nCertain patient groups warrant particular attention and monitoring, including those aged over 65 or under 18, individuals with cardiac or liver conditions, and those whose bodies metabolise medications differently.\n\nAny suspected adverse reactions should be reported through the MHRA Yellow Card scheme.\n\n**Our Standards: The GB News Editorial Charter**",
  "title": "'Check carton!' Urgent warning over antidepressant mix-up linked to nausea and headaches"
}